Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease.

BACKGROUND & AIMS In polycystic kidney disease and polycystic liver disease (PLD), the normally nonproliferative hepato-renal epithelia acquire a proliferative, cystic phenotype that is linked to overexpression of cell division cycle 25 (Cdc25)A phosphatase and cell-cycle deregulation. We investigated the effects of Cdc25A inhibition in mice and rats via genetic and pharmacologic approaches. METHODS Cdc25A(+/-) mice (which have reduced levels of Cdc25A) were cross-bred with polycystic kidney and hepatic disease 1 (Pkhd1(del2/del2)) mice (which have increased levels of Cdc25A and develop hepatic cysts). Cdc25A expression was analyzed in livers of control and polycystic kidney (PCK) rats, control and polycystic kidney 2 (Pkd2(ws25/-)) mice, healthy individuals, and patients with PLD. We examined effects of pharmacologic inhibition of Cdc25A with vitamin K3 (VK3) on the cell cycle, proliferation, and cyst expansion in vitro; hepato-renal cystogenesis in PCK rats and Pkd2(ws25/-)mice; and expression of Cdc25A and the cell-cycle proteins regulated by Cdc25A. We also examined the effects of the Cdc25A inhibitor PM-20 on hepato-renal cystogenesis in Pkd2(ws25/-) mice. RESULTS Liver weights and hepatic and fibrotic areas were decreased by 32%-52% in Cdc25A(+/-):Pkhd1(del2/del2) mice, compared with Pkhd1(del2/del2) mice. VK3 altered the cell cycle and reduced proliferation of cultured cholangiocytes by 32%-83% and decreased growth of cultured cysts by 23%-67%. In PCK rats and Pkd2(ws25/-) mice, VK3 reduced liver and kidney weights and hepato-renal cystic and fibrotic areas by 18%-34%. PM-20 decreased hepato-renal cystogenesis in Pkd2(ws25/-) mice by 15%. CONCLUSIONS Cdc25A inhibitors block cell-cycle progression and proliferation, reduce liver and kidney weights and cyst growth in animal models of polycystic kidney disease and PLD, and might be developed as therapeutics for these diseases.

[1]  Ji Liu,et al.  Inhibition of androgen receptor and Cdc25A phosphatase as a combination targeted therapy in molecular apocrine breast cancer. , 2010, Cancer letters.

[2]  N. LaRusso,et al.  Activation of Trpv4 reduces the hyperproliferative phenotype of cystic cholangiocytes from an animal model of ARPKD. , 2010, Gastroenterology.

[3]  James Glockner,et al.  Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. , 2010, Journal of the American Society of Nephrology : JASN.

[4]  R. Mancinelli,et al.  Polycystic liver diseases. , 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[5]  E. Ritman,et al.  Hepato-renal pathology in pkd2ws25/- mice, an animal model of autosomal dominant polycystic kidney disease. , 2010, The American journal of pathology.

[6]  E. Novellino,et al.  Inhibitors of Cdc25 phosphatases as anticancer agents: a patent review , 2010, Expert opinion on therapeutic patents.

[7]  M. V. van Oijen,et al.  Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. , 2009, Gastroenterology.

[8]  Bipul R. Acharya,et al.  Vitamin K3 disrupts the microtubule networks by binding to tubulin: a novel mechanism of its antiproliferative activity. , 2009, Biochemistry.

[9]  N. LaRusso,et al.  Cholangiociliopathies: genetics, molecular mechanisms and potential therapies , 2009, Current opinion in gastroenterology.

[10]  W. Ma,et al.  Novel Agents on the Horizon for Cancer Therapy , 2009, CA: a cancer journal for clinicians.

[11]  N. LaRusso,et al.  The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD) , 2009, Hepatology.

[12]  N. LaRusso,et al.  Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease. , 2008, The American journal of pathology.

[13]  S. Manenti,et al.  CDC25A: a rebel within the CDC25 phosphatases family? , 2008, Anti-cancer agents in medicinal chemistry.

[14]  P. Wipf,et al.  Is Cdc25 a druggable target? , 2008, Anti-cancer agents in medicinal chemistry.

[15]  B. Ducommun,et al.  Cell cycle control by the CDC25 phosphatases. , 2008, Anti-cancer agents in medicinal chemistry.

[16]  N. LaRusso,et al.  MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease. , 2008, The Journal of clinical investigation.

[17]  L. van Keimpema,et al.  Somatostatin analogues reduce liver volume in polycystic liver disease , 2008, Gut.

[18]  Takeshi Akiyoshi,et al.  An attempt to evaluate the effect of vitamin K3 using as an enhancer of anticancer agents. , 2008, Biological & pharmaceutical bulletin.

[19]  Hiroyuki Tomita,et al.  The utility of vitamin K3 (menadione) against pancreatic cancer. , 2008, Anticancer research.

[20]  N. LaRusso,et al.  A mouse model of autosomal recessive polycystic kidney disease with biliary duct and proximal tubule dilatation. , 2007, Kidney international.

[21]  D. Nimbalkar,et al.  Hemizygous disruption of Cdc25A inhibits cellular transformation and mammary tumorigenesis in mice. , 2007, Cancer research.

[22]  Bernard Ducommun,et al.  CDC25 phosphatases in cancer cells: key players? Good targets? , 2007, Nature Reviews Cancer.

[23]  N. LaRusso,et al.  Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate. , 2007, Gastroenterology.

[24]  V. Torres,et al.  Polycystic kidney disease: genes, proteins, animal models, disease mechanisms and therapeutic opportunities , 2007, Journal of internal medicine.

[25]  P. Wipf,et al.  Independent Mechanistic Inhibition of Cdc25 Phosphatases by a Natural Product Caulibugulone , 2007, Molecular Pharmacology.

[26]  Laurie A. Smith,et al.  Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine , 2006, Nature.

[27]  Meifang Wang,et al.  H32, a non-quinone sulfone analog of vitamin K3, inhibits human hepatoma cell growth by inhibiting Cdc25 and activating ERK , 2006, Cancer biology & therapy.

[28]  Meifang Wang,et al.  PM-20, a novel inhibitor of Cdc25A, induces extracellular signal–regulated kinase 1/2 phosphorylation and inhibits hepatocellular carcinoma growth in vitro and in vivo , 2006, Molecular Cancer Therapeutics.

[29]  Bernard Ducommun,et al.  The when and wheres of CDC25 phosphatases. , 2006, Current opinion in cell biology.

[30]  D. Wallace,et al.  Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells. , 2005, Journal of the American Society of Nephrology : JASN.

[31]  L. Antiga,et al.  Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. , 2005, Kidney international.

[32]  J. Doroshow,et al.  Phase I trial of menadiol diphosphate (vitamin K3) in advanced malignancy , 2005, Investigational New Drugs.

[33]  H. Yoshiji,et al.  Antitumor effects of vitamins K1, K2 and K3 on hepatocellular carcinoma in vitro and in vivo. , 2005, International journal of oncology.

[34]  P. Wipf,et al.  Dual specificity protein phosphatases: therapeutic targets for cancer and Alzheimer's disease. , 2005, Annual review of pharmacology and toxicology.

[35]  J. García Rodríguez,et al.  [Polycystic Kidney Disease]. , 2005, Actas urologicas espanolas.

[36]  E. Ritman,et al.  Molecular Pathogenesis of Genetic and Inherited Diseases Biliary Dysgenesis in the PCK Rat , an Orthologous Model of Autosomal Recessive Polycystic Kidney Disease , 2004 .

[37]  James P Calvet,et al.  Calcium Restriction Allows cAMP Activation of the B-Raf/ERK Pathway, Switching Cells to a cAMP-dependent Growth-stimulated Phenotype* , 2004, Journal of Biological Chemistry.

[38]  J. Rudolph,et al.  Cdc25 phosphatases and cancer. , 2004, Chemistry & biology.

[39]  P. Calderon,et al.  Inhibition of the development of metastases by dietary vitamin C:K3 combination. , 2004, Life sciences.

[40]  J. Lazo,et al.  Activation of the Raf‐1/MEK/Erk kinase pathway by a novel Cdc25 inhibitor in human prostate cancer cells , 2004, The Prostate.

[41]  J. Lazo,et al.  Regulation of Cdc25A Half-life in Interphase by Cyclin-dependent Kinase 2 Activity* , 2003, Journal of Biological Chemistry.

[42]  D. Lamson,et al.  The anticancer effects of vitamin K. , 2003, Alternative medicine review : a journal of clinical therapeutic.

[43]  J. Markovits,et al.  Differential effects of two growth inhibitory K vitamin analogs on cell cycle regulating proteins in human hepatoma cells. , 2003, Life sciences.

[44]  P. Calderon,et al.  Autoschizis: a novel cell death. , 2002, Biochemical pharmacology.

[45]  T. Sun,et al.  Vitamin K3 induces cell cycle arrest and cell death by inhibiting Cdc25 phosphatase. , 1999, European journal of cancer.